Jazz Gets Second Indication For Xywav As First Therapy For Idiopathic Hypersomnia

 
• By Joseph Haas

Following last year’s approval in cataplexy for the Xyrem follow-on, Jazz could realize additional revenue of up to $500m annually with the first and only approval in IH, analysts say.

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.
Jazz's second indication for Xywav is also the first approval in idiopathic hypersomnia

More from New Products

More from Scrip